BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,118 | -87.6% | 175,504 | +27.6% | 0.00% | – |
| Q2 2023 | $283,446 | +765970.3% | 137,595 | +1125.6% | 0.00% | – |
| Q1 2023 | $37 | -45.6% | 11,227 | -73.0% | 0.00% | – |
| Q4 2022 | $68 | -100.0% | 41,618 | -71.0% | 0.00% | – |
| Q3 2022 | $634,000 | +108.6% | 143,359 | +30.3% | 0.00% | – |
| Q2 2022 | $304,000 | -36.0% | 109,996 | -22.1% | 0.00% | – |
| Q1 2022 | $475,000 | -21.0% | 141,253 | -5.9% | 0.00% | – |
| Q4 2021 | $601,000 | +21.2% | 150,166 | -0.1% | 0.00% | – |
| Q3 2021 | $496,000 | -64.9% | 150,327 | -59.5% | 0.00% | -100.0% |
| Q2 2021 | $1,412,000 | +493.3% | 371,460 | +605.4% | 0.00% | – |
| Q4 2020 | $238,000 | +47.8% | 52,662 | +266.4% | 0.00% | – |
| Q2 2020 | $161,000 | -82.5% | 14,373 | -92.7% | 0.00% | -100.0% |
| Q1 2020 | $919,000 | – | 198,052 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 241,500 | $1,093,000 | 0.17% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 90,584 | $410,000 | 0.13% |
| EPIQ PARTNERS, LLC | 10,550 | $48,000 | 0.03% |
| Phoenix Holdings Ltd. | 173,683 | $799,000 | 0.02% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 5,500 | $25,000 | 0.02% |
| CFO4Life Group, LLC | 12,003 | $54,000 | 0.02% |
| HighPoint Advisor Group LLC | 15,733 | $115,000 | 0.01% |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 357,761 | $1,619,000 | 0.01% |
| Virtu Financial LLC | 24,484 | $111,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 93,902 | $435,000 | 0.01% |